Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The
acute efficacy of ketamine in TRD has been demonstrated in replicated randomised …

The monoamine hypothesis has been accepted as the most common hypothesis of major
depressive disorder (MDD) for a long period because of its simplicity and understandability …

Objective: The authors conducted a systematic review and meta-analysis of ketamine and
other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major …

Objective The current meta‐analysis examines the effects of ketamine infusion on
depressive symptoms over time in major depressive disorder (MDD) and bipolar disorder …

Background: At least 10-20% of the patients suffering from depression meet criteria for
treatment-resistant depression (TRD). In the last decades, an important role of glutamate in …

Since publication of the first randomized controlled trial describing rapid antidepressant
effects of ketamine, several reports have confirmed the potential utility of this dissociative …

Currently available drugs for unipolar major depressive disorder (MDD), which target
monoaminergic systems, have a delayed onset of action andsignificant limitations in …

Existing treatments for major depressive disorder (MDD) usually take weeks to months to
achieve their antidepressant effects, and a significant number of patients do not have …

Mood disorders such as bipolar disorder and major depressive disorder are common,
chronic, and recurrent conditions affecting millions of individuals worldwide. Existing …

Several studies have supported the idea that ionotropic glutamate N-methyl-d-aspartate
receptor (NMDA) is an important player in the etiology of psychopathologies, such as anxiety …